BHC Bausch Health Companies Inc.
Mergers ·
BHC Lyon accepted 19,984,767 DURECT shares and merged into DURECT on September 11, 2025. Holders get $1.75 per share in cash plus a contingent value right that pays only if net sales milestones are reached.
Bausch Health's subsidiary launched a $4.0 billion offering of senior secured notes due 2032, and the parent began syndicating new secured credit facilities. The proceeds would retire 2025 and 2027 debt, but the filing gives no interest rate on the new notes or the term loan.
Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. It develops, manufactures and markets branded, generic and branded generic pharmaceuticals, over-the-counter products and aesthetic medical devices, primarily in gastroenterology, hepatology, neurology and dermatology. Through its approximately 88% ownership of Bausch + Lomb Corporation, it also markets eye health products. Its products are marketed in approximately 90 countries and fall into five reportable segments: Salix, International, Solta Medical, Diversified and Bausch + Lomb. Its Xifaxan product line, indicated for irritable bowel syndrome with diarrhea and for reducing the risk of overt hepatic encephalopathy recurrence, represents approximately 85% of Salix segment revenues. Other principal products include Relistor, for constipation in adults using narcotic medicine for chronic pain, and Trulance, a once-daily tablet for chronic idiopathic constipation. Revenues were $10,266 million in 2025, and the company has approximately 1,000 products in its portfolio.
| Product or program | What it is | Stage |
|---|---|---|
| Xifaxan | Tablets for IBS-D, hepatic encephalopathy recurrence and travelers' diarrhea | |
| Relistor (methylnaltrexone) | Prevents constipation in adults using narcotic medicine for chronic pain | |
| Trulance (plecanatide) | Once-daily tablet for chronic idiopathic constipation |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $629.0 million | $616.0 million |
| Net income (loss) | $157.0 million | -$46.0 million |
| Cash from operations | $1.40 billion | $1.60 billion |
| Cash and equivalents | $1.31 billion | $1.18 billion |
Our latest story on this, dated Mar 19, 2025: "Bausch Health launches $4.0 billion senior secured notes offering to refinance debt". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 11, 2025: "Bausch Health completes DURECT acquisition after tender offer draws about 62% of shares". The story links the filing or release it is based on. Read the story.
Bausch Health Companies Inc. trades under the ticker BHC on TSX.
Bausch Health Companies Inc. is listed on TSX. Our directory also records these other listings: BMV:BHC/N; GETTEX:BVF; LSX:A2JQ1X; NEO:BHC; NYSE:BHC.
The SEC Central Index Key (CIK) for Bausch Health Companies Inc. is 885590. Its filings are on SEC EDGAR.
373,990,561 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-07-30.
Our directory records Bausch Health Companies Inc. under Canada.
Our directory classifies Bausch Health Companies Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Bausch Health Companies Inc. is CA0717341071.
aibio.space lists Bausch Health Companies Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NJ.
Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. It develops, manufactures and markets branded, generic and branded generic pharmaceuticals, over-the-counter products and aesthetic medical devices, primarily in gastroenterology, hepatology, neurology and dermatology.
Xifaxan: Tablets for IBS-D, hepatic encephalopathy recurrence and travelers' diarrhea
Relistor (methylnaltrexone): Prevents constipation in adults using narcotic medicine for chronic pain
Bausch Health Companies Inc. reported net income of $157.0 million for the fiscal year ended Dec 31, 2025, and generated $1.40 billion of cash from operations, per its annual report to the SEC.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio